araag2/HINT huggingface dataset:
Clinical trial NCT01558492 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of prostate carcinoma.

          -  Subject must have progressive metastatic prostate cancer despite adequate medical or
             surgical castration therapy. Furthermore, if applicable, medical castration must be
             maintained for the duration of the protocol.

          -  Serum testosterone < 50 ng/ml.

          -  Subjects who have received anti-androgen therapy with a resulting PSA decline must
             demonstrate progression following discontinuation of anti-androgen therapy.

          -  Subjects capable of fathering children must agree to use an effective method of
             contraception for the duration of the trial.

          -  Must have previously received docetaxel for prostate cancer

          -  ECOG performance status 0-2

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Platelet count <100,000/mm3

          -  Absolute neutrophil count (ANC) <1,500/mm3

          -  Hemoglobin < 8 g/dL

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x upper limit
             of normal

          -  Bilirubin (total) >2 x upper limit of normal. Subjects with known Gilbert's syndrome
             are eligible if direct bilirubin is within normal limits

          -  For subjects with serum creatinine > 1.5 x ULN, calculated creatinine clearance < 30
             ml/min are excluded; subjects meeting this exclusion criterion are eligible if a
             measured clearance is > 30 ml/min

          -  Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or
             hematological organ systems which might preclude completion of this study or interfere
             with determination of causality of any adverse effects experienced in this study

          -  Prior investigational therapy within 4 weeks of treatment. Furthermore, other
             investigational anti-cancer therapy is not permitted during the treatment phase.

          -  Grade > 1 peripheral neuropathy
Clinical trial NCT00063570 (phase 2, status: completed)
Conditions: breast cancer, breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pemetrexed, gemcitabine, gemcitabine, pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).

          -  Less than 3 different chemotherapy treatments for metastatic disease.

          -  Prior treatment with hormonal and/or radiation therapy.

          -  Must have disease that can be measured.

          -  Must be able to take care of self needs for example personal hygiene

        Exclusion Criteria:

          -  Must not be pregnant or breast-feeding.

          -  Cancer that has spread to the brain.

          -  Treatment with Gemcitabine or Pemetrexed

          -  Unable to take folic acid or Vitamin B12

          -  Treatment for another cancer within the last 5 years
Clinical trial NCT00528697 (phase 2, status: completed)
Conditions: attention-deficit/hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: abt-089, atomoxetine, placebo
SMILES: CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have voluntarily signed an informed consent form

          -  Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on
             detailed evaluation and interview with parent(s)

          -  First grade or higher in a school setting 3 days/week

          -  Subject is generally in good health based on medical history, physical examination,
             clinical lab tests, and ECG

          -  Subject weighs at least 37 pounds (17 kg)

          -  Female subjects of childbearing potential must have a negative urine pregnancy test at
             screening and baseline and agree to comply with applicable contraceptive requirements

          -  Subject and parents have been judged by the study doctor to be reliable to keep
             required appointments for clinic visits and all tests, including blood draws, and
             examinations

        Exclusion Criteria:

          -  Subject is not functioning at an age-appropriate level intellectually

          -  Subject has a current or past diagnosis of bipolar disorder, psychosis, autism,
             Asperger's syndrome, or pervasive developmental disorder

          -  Current diagnosis of obsessive-compulsive disorder, eating disorder, anxiety disorder
             or depressive disorder requiring treatment of any kind

          -  Subject has a history of significant allergic reaction to any drug

          -  Subject requires ongoing treatment with any psychiatric medication

          -  Subject has a serious medical condition, seizure disorder (except febrile seizures as
             an infant), or history of substance abuse or dependence
Clinical trial NCT00313183 (phase 2, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: pramlintide acetate
SMILES: [H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 1 diabetes mellitus for at least 1 year prior to screening

          -  Be on a stable regimen requiring multiple daily injections of basal and mealtime
             insulin or continuous subcutaneous insulin infusion for at least 2 weeks prior to
             screening

          -  HbA1c between 6.0% and 10.0%, inclusive, at screening

          -  Body weight >=50 kg at screening

        Exclusion Criteria:

          -  Currently being treated with the following medications: *Any oral antihyperglycemic
             agent; *Drugs that directly affect gastrointestinal motility

          -  Has been previously treated with Symlin/pramlintide (or has participated in a
             Symlin/pramlintide clinical study)

          -  Has received any investigational drug within 1 month of screening
Clinical trial NCT00003487 (phase 2, status: terminated)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: antineoplaston a10, antineoplaston as2-1
SMILES: O=C(CC1=CC=CC=C1)N[C@H]1CCC(=O)NC1=O
Reason stopped: 
    withdrawn due to slow enrollment
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the esophagus that is unlikely to respond
             to existing therapy and for which no curative therapy exists

          -  Meets 1 of the following criteria:

               -  Metastatic disease

               -  Not curable with surgery or radiotherapy

          -  Measurable disease by MRI or CT scan

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  WBC at least 2000/mm3

          -  Platelet count at least 50,000/mm3

        Hepatic:

          -  No hepatic failure

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT and SGPT no greater than 5 times upper limit of normal

        Renal:

          -  Creatinine no greater than 2.5 mg/ml

          -  No history of renal conditions that contraindicate high dosages of sodium

        Cardiovascular:

          -  No chronic or congestive heart failure

          -  No uncontrolled hypertension

          -  No other cardiovascular conditions that contraindicate high dosages of sodium

        Pulmonary:

          -  No serious lung disease, such as severe chronic obstructive pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 4 weeks after study
             participation

          -  No medical illness, psychiatric illness, or non-malignant systemic disease that would
             preclude study treatment

          -  No active infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy and recovered

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

        Endocrine therapy:

          -  Concurrent steroids allowed

        Radiotherapy:

          -  At least 8 weeks since prior radiotherapy (except in patients with multiple tumors who
             have received radiotherapy to some of their tumors) and recovered

        Surgery:

          -  Recovered from prior surgery

        Other:

          -  No prior antineoplaston therapy

          -  Prior cytodifferentiating agents allowed
Clinical trial NCT00542022 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: mk0812 / duration of treatment: 12 weeks, comparator: placebo (unspecified) / duration of treatment: 12 weeks
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has had diagnosis of RA made at least 6 months prior to study start and was
             greater than 16 years of age when diagnosed

          -  Patient has active RA with a minimum level of disease activity including at least 10
             swollen joints and 10 tender or painful joints

          -  Excepting rheumatoid arthritis, patient is judged to be in otherwise general good
             health based on medical history, physical examination, and routine laboratory tests

        Exclusion Criteria:

          -  Patient is mentally or legally incapacitated, has significant emotional problems at
             the time of the study, or has a history of psychosis

          -  Patient has a history of any clinically significant disease of the cardiovascular,
             hepatic, neurological, renal, genitourinary, or hematologic systems or uncontrolled
             blood pressure

          -  Female patient is pregnant or breast-feeding
Clinical trial NCT00168896 (phase 2/phase 3, status: unknown status)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin plus irinotecan vs carboplatin plus etoposide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  cytological or histological proven SCLC Stage I or II at 1st diagnosis

          -  no prior chemotherapy

          -  measurable tumor disease

          -  karnofsky performance 70

        Exclusion Criteria:

          -  second malignancy ( except basal cell carcinoma, CA in situ Cervix uteri)

          -  NYHA III

          -  chronic diarrhea, obstructive bowel syndrome
Clinical trial NCT01454349 (phase 1/phase 2, status: completed)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: prx302, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Lower Urinary Tract Symptoms (LUTS) attributable to BPH for ≥6 months

          -  Written informed consent prior to enrollment in the study

          -  IPSS ≥12

          -  Prostate volume of 30 - 100 mL as determined by TRUS

          -  Maximum urine flow (Qmax) of 4 - 15 mL/sec

          -  Refractory, intolerant or refused the use of alpha-blockers and/or 5 alpha-reductase
             inhibitors

          -  Unwilling or unable to undergo conventional surgical or available minimally invasive
             treatments

          -  Blood PSA values <10 ng/mL

        Exclusion Criteria:

          -  Inability to void at least 125 mL of urine

          -  PVR volume >200 mL

          -  Presence of or history of certain conditions that could interfere with study results
             or endanger subject

          -  Use of certain prescribed medications that could interfere with study results
Clinical trial NCT00506948 (phase 2, status: terminated)
Conditions: hematological malignancies, myelodysplastic syndrome, leukemia, lymphoma
ICD codes: P61.9, P61.8, O28.0, T45.8X6S, T45.96XS, T45.8X3S, T45.8X4S, D46.9, D46.C, D46.Z, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: mycophenolate mofetil (mmf), thymoglobulin, sirolimus
SMILES: COC(=O)\C=C\C(O)=O, NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Reason stopped: 
    halted due to high incidence of veno-oclusive disease of the liver.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with high risk hematological malignancies, including those with induction
             failure and after treated or untreated relapse. High risk hematological malignancies
             include: Acute myelogenous or lymphocytic leukemia with induction failure of after
             relapse, myelodysplastic syndrome of intermediate and high risk according to Greenberg
             criteria, chronic myelogenous leukemia in accelerated phase or blast crisis,
             non-Hodgkin's and Hodgkin's lymphoma with induction failure or relapse after
             chemotherapy and refractory or relapsed chronic lymphocytic leukemia.

          2. HLA-identical sibling or matched unrelated donor transplants not eligible for
             protocols of higher priority.

          3. Age 18-75 years.

          4. Bilirubin </=1.5 mg/dl, serum glutamic-pyruvic transaminase (SGPT) </= 200 IU/ml.

          5. Creatinine </=1.6 mg/dl.

        Exclusion Criteria:

          1. Regimens including rituximab or alemtuzumab in the preparative regimen.

          2. Patients can not have received prior treatment with gemtuzumab.

          3. Planned conditioning chemotherapy for transplant can not include gemtuzumab.

          4. Planned conditioning chemotherapy for transplant can not include the busulfan and
             cyclophosphamide regimen.

          5. HIV seropositivity

          6. Uncontrolled infection, not responding to adequate antimicrobial therapy after 7 days
             of treatment. The protocol PI is the final arbiter of eligibility.

          7. Pregnancy

          8. Inability to sign consent.

          9. Patients who are past recipients of allogeneic or autologous stem cell transplants
             from any source.
Clinical trial NCT00715455 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: reg1, reg1, unfractionated heparin
SMILES: COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O, COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females scheduled for non-urgent elective PCI (who do not have certain
             cardiac parameters) and have not been treated with UHF prior to PCI.

          -  Subject able to give informed consent and comply with the protocol.

          -  Negative urine pregnancy test or documented surgical sterilization or menopausal.

        Exclusion Criteria:

          -  Subject weight >120 kg.

          -  Recent acute coronary syndrome with elevated cardiac markers or ST segment depression
             at rest.

          -  Evidence of clinical instability

          -  Angiographic high-risk.

          -  A contraindication to anticoagulation or increased risk of bleeding.

          -  Use of prohibited medications or investigational drugs prior to the study.

          -  Clinically significant abnormal laboratory findings.

          -  Planned use of femoral sheath greater than a certain size.

          -  Known allergy or intolerance to drugs mandated by the study.

          -  Use of devices other than angioplasty balloons and coronary stents.

          -  A history of licit drug abuse or illicit drug use or current evidence of such abuse.

          -  Any other factor that the Investigator feels would put the subject at increased risk
             if participating in the protocol.

          -  Lactation.

          -  Currently enrolled in this or another clinical trial (with some exceptions).

          -  Participation in an investigational drug or device trial in the past 30 days.
Clinical trial NCT01194245 (phase 2, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin lispro, recombinant human hyaluronidase ph20, insulin aspart, insulin glulisine, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females aged ≥18 years

          -  Type 1 Diabetes Mellitus (T1DM) treated with insulin for ≥12 months

          -  Body mass index (BMI) 18.0 to 40.0 kilograms per square meter (kg/m^2).

          -  Hemoglobin A1C (HbA1C) level 6.7% to 8.2%, inclusive

          -  Fasting C-peptide <0.6 nanograms per milliliter (ng/mL)

          -  Willingness to use twice daily (BID) insulin glargine as basal insulin for the
             duration of the study

          -  Willingness to avoid use of an insulin infusion pump or unblinded continuous glucose
             monitoring (CGM) during the study

        Exclusion Criteria:

          -  Known or suspected allergy to any component of any of the study drugs

          -  Use of pramlintide within 30 days of Screening

          -  Use of drugs during the study or within 30 days of Screening (such as corticosteroids
             or antimetabolites) that could interfere with the interpretation of study results or
             are known to cause clinically relevant interference with insulin action, glucose
             utilization, or recovery from hypoglycemia

          -  Recurrent severe hypoglycemia (more than 2 episodes over the last 6 months) or
             hypoglycemic unawareness, as judged by the Investigator
Clinical trial NCT00377455 (phase 2, status: terminated)
Conditions: systemic scleroderma, pulmonary hypertension
ICD codes: L94.1, L94.0, I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: bosentan, placebo
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study was terminated due to inadequate enrolment
  
Eligibility criteria:

        Inclusion Criteria:

          -  SSc patients > 18 with NYHA functional Class I/II symptoms, informed consent, and who
             are willing to participate in the Pulmonary Hypertension Assessment and Recognition of
             Outcomes in Scleroderma (PHAROS) long term study (Georgetown IRB 04-227)

          -  Right heart catheterization with

               1. Normal Mean Pulmonary Arterial Pressure (PAP) at rest

               2. Mean PAP > 30 with exercise

               3. Wedge Pressure < 18

          -  Entry criteria for participating in the exercise echocardiogram study (Georegtown IRB
             03-363)

               1. Diffusing Capacity (DLCO) <60 with a Forced Vital Capacity (FVC) >60%, or

               2. FVC/DLCO > 1.6, or

               3. a resting Pulmonary Arterial Systolic Pressure (PASP)> 40mmHg

        Exclusion Criteria:

          -  Established resting pulmonary hypertension

          -  Congestive heart failure

          -  Diastolic dysfunction

          -  Pregnancy

          -  Inability to adequately walk/exercise

          -  Severe liver disease
Clinical trial NCT01234558 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: glyx-13
SMILES: C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of major depressive disorder consistent with DSM-IV-TR

          -  current episode greater than 8 weeks in duration

          -  Hamilton Depression score >/- 21

          -  less than 25% reduction in depression during current episode assessed by ATRQ

        Exclusion Criteria:

          -  Axis diagnosis of other psychiatric disorders

          -  Experiencing hallucinations, delusions, other psychotic symptomatology

          -  ECT during current episode
Clinical trial NCT00041574 (phase 2, status: terminated)
Conditions: pulmonary hypertension, lung disease, sickle cell disease, cardiac transplant, lung transplant
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22, J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218, T86.11, T86.12, T86.13, T86.21, T86.22, T86.23, T86.41
Drugs: inhaled nitric oxide
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O
Reason stopped: 
    closed for lack of enrollment
  
Eligibility criteria:

        Inclusion criteria:

          -  Patients with pulmonary arterial hypertension (PAH) as defines by a mean pulmonary
             artery pressure (PAP) of 25 mmHg or greater by cardiac catheterization within the
             previous 12 months AND/OR Patients with chronic lung disease with severe impairment of
             gas exchange unresponsive to conventional medical management.

          -  If patient is receiving prostacyclin infusion treatment it must have been started at
             least one month prior to starting INO therapy. Patients will not be withdrawn from the
             study if started on other medications for treatment of pulmonary hypertension.

          -  Ability to establish a clinical investigator and a drug shipment site in the local
             area.

        Exclusion Criteria:

          -  The Principal Investigator has determined that the patient and/or caregiver is/are
             unable to manage safe administration of home nitric oxide therapy and maintain
             appropriate drug accountability and storage.

          -  Women who are pregnant or nursing.